Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Status:
Recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once
the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory
grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Georgetown University
Collaborators:
AbbVie Hackensack Meridian Health Hackensack University Medical Center Pharmacyclics LLC.